This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.
本公开涉及新型
吗啡南化合物及其衍
生物、其药学上可接受的盐、溶液剂和
水合物。本公开还提供了包含本公开化合物的组合物,以及这些组合物在治疗疾病和病症的方法中的用途,这些疾病和病症可通过施用同时具有 N
MDA 拮抗剂活性的 σ1 受体激动剂得到有益治疗。